Endocrinol Metab.  2023 Feb;38(1):72-74. 10.3803/EnM.2023.106.

The 2017 United States Preventive Services Task Force Recommendation for Thyroid Cancer Screening Is No Longer the Gold Standard

• Yi KH

• KMID: 2539819
• DOI: http://doi.org/10.3803/EnM.2023.106

Reference

1. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, et al. Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA. 2017; 317:1882–7.

2. Lin JS, Bowles EJ, Williams SB, Morrison CC. Screening for thyroid cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017; 317:1888–903.

3. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003; 13:381–7.

4. Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010; 34:28–35.

5. Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014; 24:27–34.

6. Lee YS, Lim H, Chang HS, Park CS. Papillary thyroid microcarcinomas are different from latent papillary thyroid carcinomas at autopsy. J Korean Med Sci. 2014; 29:676–9.

7. Lang BH, Wong IO, Wong KP, Cowling BJ, Wan KY. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012; 151:844–50.

8. Hakala TT, Sand JA, Jukkola A, Huhtala HS, Metso S, Kellokumpu-Lehtinen PL. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Int J Clin Oncol. 2016; 21:231–9.

9. Lin CY, Lin CL, Huang WS, Kao CH. Risk of breast cancer in patients with thyroid cancer receiving or not receiving 131I treatment: a nationwide population-based cohort study. J Nucl Med. 2016; 57:685–90.

10. Seo GH, Cho YY, Chung JH, Kim SW. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea. Thyroid. 2015; 25:927–34.

11. Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. Clin Endocrinol (Oxf). 2015; 83:117–23.

12. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016; 26:1–133.

13. Hsiao V, Light TJ, Adil AA, Tao M, Chiu AS, Hitchcock M, et al. Complication rates of total thyroidectomy vs hemithyroidectomy for treatment of papillary thyroid microcarcinoma: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2022; 148:531–9.

14. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012; 366:1663–73.

15. Moon S, Lee EK, Choi H, Park SK, Park YJ. Survival Comparison of incidentally found versus clinically detected thyroid cancers: an analysis of a nationwide cohort study. Endocrinol Metab (Seoul). 2023; 38:81–92.

16. Moon S, Song YS, Jung KY, Lee EK, Park YJ. Lower thyroid cancer mortality in patients detected by screening: a meta-analysis. Endocrinol Metab (Seoul). 2023; 38:93–103.

17. Hsiao V, Massoud E, Jensen C, Zhang Y, Hanlon BM, Hitchcock M, et al. Diagnostic accuracy of fine-needle biopsy in the detection of thyroid malignancy: a systematic review and meta-analysis. JAMA Surg. 2022; 157:1105–13.

18. Joo L, Lee MK, Lee JY, Ha EJ, Na DG. Diagnostic performance of ultrasound-based risk stratification systems for thyroid nodules: a systematic review and meta-analysis. Endocrinol Metab (Seoul). 2023; 38:117–28.